340B Drug Spending Rose From $6.6 Billion In 2010 To $43.9 Billion In 2021

Spending on drugs purchased through the 340B Drug Pricing Prime Vendor Program (PVP) increased from $6.6 billion in 2010 to $43.9 billion in 2021, according to a recent report by the Congressional Budget Office (CBO). One-third of the spending increase was attributed to a combination of marketwide growth in drug spending plus what the report described as disproportionate growth among drug classes that account for more spending in the 340B program than in the overall market.

In 2021, 61% of the participating facilities were hospital-based, and drugs purchased by those facilities and affiliated pharmacies accounted for . . .